MRK vs NVDA: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and NVIDIA Corporation โ fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Merck & Co., Inc. ยท Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
NVIDIA Corporation ยท Technology
$182.08
+59.3% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
NVDA has more upside to fair value
(+59.3%).
These are model outputs โ not personalized investment advice.
See all research โ
Valuation & Fundamentals
| Metric |
MRK |
NVDA |
| Current Price |
$121.42 |
$182.08 |
| Fair Value Estimate |
$118.00 |
$290.00 |
| Upside to Fair Value |
-2.9%
|
+59.3%
|
| Market Cap |
$300.2B |
$4,425.5B |
| Forward P/E |
14.0x
|
โ
|
| EV / EBITDA |
11.8x
|
31.4x
|
| Price / Sales |
4.1x
|
21.0x
|
| Price / FCF |
21.4x
|
46.9x
|
| Revenue Growth YoY |
+1.3%
|
+65.5%
|
| Gross Margin |
81.5%
|
71.1%
|
| Operating Margin |
41.2%
|
60.4%
|
| Return on Equity |
34.7%
|
76.3%
|
| Dividend Yield |
3.1% |
0.02% |
| FCF Yield |
4.7%
|
2.13%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7โฆ
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x vโฆ
Accumulation Zones
| Metric |
MRK |
NVDA |
| Zone Low |
$88.00 |
$218.00 |
| Zone High |
$100.00 |
$250.00 |
| In Buy Zone? |
No
|
Yes
|